Subjects must meet all of the following applicable inclusion criteria to participate in the
        study.

        Inclusion Criteria:

          -  Histologically confirmed transitional cell (urothelial) carcinoma of the bladder that
             is invasive into the muscularis propria (≥T2 disease) within 6 months of enrollment
             date. The presence of variant histologies (squamous, adenocarcinoma, micropapillary,
             etc.) is allowed. Note: A prior diagnosis of non-muscle-invasive bladder cancer (≤T1)
             managed with transurethral resection with or without intravesicular therapy (now with
             muscle invasion) is allowed.

          -  Inability to receive cisplatin-based chemotherapy, as defined by creatinine clearance
             <60 ml/min, ECOG PS ≤2, grade 2 or higher hearing loss, NYHA class 3 or higher,
             neuropathy (grade 2 or higher), or patient refusal to receive cisplatin-based
             chemotherapy.

        Additional Inclusion Criteria:

          -  Male or female subjects aged ≥18 years

          -  ECOG performance status ≤2 or Karnofsky score ≥60% (see Appendix A)

          -  Life expectancy of greater than 1 year

          -  Demonstrate normal organ and marrow function

          -  Women of child-bearing age must have a negative serum pregnancy test at screening.

          -  Women of child-bearing potential and men must agree to use a highly effective method
             of contraception (hormonal or barrier method of birth control, or abstinence)
             beginning prior to study entry, for the duration of study participation, and for at
             least 30 days after last avelumab treatment administration if the risk of conception
             exists

          -  Ability to understand and willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Prior intravenous therapy for treatment of bladder cancer

          -  Prior pelvic radiation

          -  Any component of small cell histology in the bladder biopsy

          -  Any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment

          -  Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal,
             inhaled, topical steroid, or local steroid injection (e.g., intra-articular
             injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone
             or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT
             scan premedication) are allowed.

          -  History of another malignancy within 5 years prior to randomization except for:
             non-muscle-invasive bladder cancer (i.e., ≤T1), completely resected basal cell or
             squamous cell skin cancer, completed resected carcinoma-in-situ of any site, or
             localized prostate cancer managed definitively with a non-radiation based approach.

        Additional Exclusion Criteria:

          -  Evidence of lymph node involvement or metastatic disease on CT of the chest, abdomen,
             and pelvis. To be considered positive, a lymph node must measure >15 mm in short axis.

          -  Clinically significant (i.e. active) cardiovascular disease: symptomatic congestive
             heart failure (≥ New York Heart Association Classification Class II), unstable angina
             pectoris, serious cardiac arrhythmia requiring medication, or CVA/stroke/MI (< 6
             months prior to enrollment)

          -  Known prior severe hypersensitivity to investigational product or any component in its
             formulations, including known severe hypersensitivity reactions to monoclonal
             antibodies (NCI CTCAE v4.03 Grade ≥ 3)

          -  Breast feeding women who are unwilling to stop breastfeeding during treatment and for
             at least one month after the duration of treatment

          -  Patients with known history of testing positive for HIV or known acquired
             immunodeficiency syndrome

          -  Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory
             agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid
             diseases not requiring immunosuppressive treatment are eligible.

          -  Active infection requiring intravenous antibiotic therapy

          -  Vaccination within 4 weeks of the first dose of avelumab and while on trial is
             prohibited except for administration of inactivated vaccines

          -  Major surgery within the last 30 days (with the exception of TURBT).

          -  Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive
             HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)

          -  Prior organ transplantation including allogenic stem-cell transplantation

          -  Patient is unwilling to stop (or wishes to start) taking herbal and natural remedies
             that may have immune-modulating effects during the study period

          -  Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however,
             alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety
             risk based on investigator's judgment are acceptable

          -  Other severe acute or chronic medical conditions including immune colitis,
             inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric
             conditions including recent (within the past year) or active suicidal ideation or
             behavior; or laboratory abnormalities that may increase the risk associated with study
             participation or study treatment administration or may interfere with the
             interpretation of study results and, in the judgment of the investigator, would make
             the patient inappropriate for entry into this study.

          -  Pregnant women are excluded from this study.